Archives of Toxicology

, Volume 84, Issue 5, pp 411–420 | Cite as

A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods

Genotoxicity and Carcinogenicity

Abstract

Fluoroquinolones (FQ) are broad-spectrum antibacterial agents widely used for the treatment of infections with various types of gram negative and gram positive bacteria. Specifically, gatifloxacin (GFX) is under development as a component in a new antituberculosis fixed-dose drug combination. In the context of this project, GFX was also tested for genotoxic activity in human peripheral lymphocytes, and the induction of chromosomal aberrations by GFX in PHA-M stimulated cultured human lymphocytes, investigated under conditions of conventional and increased expression times, was further compared to the analogous effects induced by some other second- and third-generation FQ antibacterial agents, namely ofloxacin (OFX), ciprofloxacin (CFX) and sparfloxacin (SFX). OFX did not induce any significant chromosomal aberrations in human lymphocytes. CFX and SFX exhibited slight to moderate clastogenic potential at cytotoxic concentrations (150, 175, 200 and 225 μg/ml), and GFX, a third-generation FQ, induced a clear, concentration-dependent increase in the frequency of chromosomal aberrations at cytotoxic concentrations (150, 200 and 250 μg/ml). These effects were not apparent when metaphases were analysed at the conventionally used sampling time of 24 h, but only after prolongation of the expression time between treatment and harvesting to a sampling time of 36 h (4 h exposure and 32 h expression period). Also, an increased incidence of numerical aberrations (polyploidy and endoreduplication) was seen with GFX at non-cytotoxic concentrations (12.5, 25, 50 and 75 μg/ml). These effects can be attributed to the slight cross-reactivity of FQs between their inhibitory activity towards their intended targets, the prokaryotic type II topoisomerase enzymes DNA gyrase and topoisomerase IV, and the analogous mammalian enzyme topoisomerase II. We have also observed the formation of polycentrics, i.e., chromosomes with five to six centromeres, a rarely reported structural aberration, in GFX-treated cells. The significance of these observations with respect to the conventional conduct of such studies and to the interpretation of the effects is discussed.

Keywords

Gatifloxacin Ciprofloxacin Ofloxacin Sparfloxacin Chromosomal aberration Human lymphocyte 

Abbreviations

GFX

Gatifloxacin

CFX

Ciprofloxacin

OFX

Ofloxacin

SFX

Sparfloxacin

FQ

Fluoroquinolone

MMC

Mitomycin C

BrdU

5-bromo-2-deoxyuridine

DMSO

Dimethylsulphoxide

FBS

Foetal bovine serum

PHA-M

Phytohaemagglutinin

MI

Mitotic index

RI

Replicative index

SCE

Sister chromatid exchange

References

  1. Albertini S, Chételat A-A, Miller B, Muster W, Pujadas E, Strobel R, Gocke E (1995) Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems. Mutagenesis 10:343–351CrossRefPubMedGoogle Scholar
  2. Anupama M, Murugan SS, Murthy PB (2008) Broccoli flower head extract reduces Mitomycin-c induced sister chromatid exchange in cultured human lymphocytes. Food Chem Toxicol 46:3351–3353CrossRefPubMedGoogle Scholar
  3. Appelbaum PC, Hunter PA (2000) The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 16(1):5–15CrossRefPubMedGoogle Scholar
  4. Aubry A, Pan X-S, Fisher ML, Jarlier V, Cambau E (2004) Mycobacterium tuberculosis DNA Gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 48:1281–1288CrossRefPubMedGoogle Scholar
  5. Auf der Maur P, Berlincourt-Böhni K (1979) Human lymphocyte cell cycle: studies with the use of BrUdR. Hum Genet 49:209–215PubMedGoogle Scholar
  6. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379:225–232CrossRefPubMedGoogle Scholar
  7. Cantero G, Campanella C, Mateos S, Cortés F (2006) Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin. Mutagenesis 21(5):321–325CrossRefPubMedGoogle Scholar
  8. Clarke DJ, Johnson RT, Downs CS (1993) Topoisomerase II inhibition prevents anaphase chromatid segregation in mammalian cells independently of the generation of DNA strand breaks. J Cell Sci 105:563–568PubMedGoogle Scholar
  9. Cortés F, Pastor N (2003) Induction of endoreduplication by topoisomerase II catalytic inhibitors. Mutagenesis 18(2):105–112CrossRefPubMedGoogle Scholar
  10. Curry PT, Kropko ML, Garvin JR, Fiedler RD, Theiss JC (1996) In vitro induction of micronuclei and chromosome aberrations by quinolones: possible mechanisms. Mutat Res 352:143–150PubMedGoogle Scholar
  11. Downes CS, Mullinger AM, Johnson RT (1991) Inhibitors of DNA topoisomerase II prevent anaphase chromatid separation in mammalian cells but do not prevent exit from mitosis. Proc Natl Acad Sci USA 88:2616–2620CrossRefGoogle Scholar
  12. Drlica K, Malik M (2003) Fluoroquinolones: action and resistance. Curr Top Med Chem 3:249–282CrossRefPubMedGoogle Scholar
  13. Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N (1993) Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother 37(10):2179–2186PubMedGoogle Scholar
  14. EMEA, European Medicines Evaluation Agency (2006) Guideline on the limits of genotoxic impurities. EMEA/CHMP/QWP/251344/2006, London, 28 June 2006Google Scholar
  15. Evans HJ (1984) Human peripheral blood lymphocytes for the analysis of chromosome aberration in Mutagen tests. In: Kilbey BJ, Legator MS, Nichols W, Ramel C (eds) Handbook of mutagenicity test procedures, 2nd edn. Elsevier, Amsterdam, pp 405–427Google Scholar
  16. Galloway SM, Aardema MJ, Ishidate M Jr, Ivett JL, Kirkland DJ, Morita T, Mosesso P, Sofuni T (1994) Report from working group on in vitro tests for chromosomal aberrations. Mutat Res 312:241–261PubMedGoogle Scholar
  17. Gorla N, Garcia Ovando H, Larripa I (1999) Chromosomal aberrations in human lymphocytes exposed in vitro to enrofloxacin and ciprofloxacin. Toxicol Lett 104:43–48CrossRefPubMedGoogle Scholar
  18. Guillemin I, Sougakoff W, Cambau E, Revel-Viravau V, Moreau N, Jarlier V (1999) Purification and inhibition of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. Peregrinum. Microbiology 145:2527–2532PubMedGoogle Scholar
  19. Hayasaki Y, Itoh S, Kato M, Furuhama K (2006) Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2 uvrA/pKM101. Toxicol In Vitro 20:342–346CrossRefPubMedGoogle Scholar
  20. Henderson L, Albertini S, Aardema M (2000) Thresholds in genotoxicity responses. Mutat Res 464:123–128PubMedGoogle Scholar
  21. Herbold BA, Brendler-Schwaab SY, Ahr HJ (2001) Ciprofloxacin: in vivo genotoxicity studies. Mutat Res 498:193–205PubMedGoogle Scholar
  22. Hooper DC (1999) Mode of action of fluoroquinolones. Drugs 58(2):6–10CrossRefPubMedGoogle Scholar
  23. Hoshino K, Kitamura A, Morissey I, Sato K, Kato J-I, Ikeda H (1994) Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 38:2623–2627PubMedGoogle Scholar
  24. Huang CC, Hou Y, Wang JJ (1973) Effect of a new antitumor agent, epipodophyllotoxin, on growth and chromosome in human hematopoietic cell lines. Cancer Res 33:3123–3129PubMedGoogle Scholar
  25. IARC (2000) IARC Monograph on the evaluation of carcinogenic risks to humans: some antineoplastic and immunosuppressive agents, vol 76. International Agency for Research on Cancer, Lyon, pp 177–258Google Scholar
  26. Itoh T, Mitsumori K, Kawaguchi S, Sasaki YF (2006) Genotoxic potential of quinolone antimicrobials in the in vitro comet assay and micronucleus test. Mutat Res 603:135–144PubMedGoogle Scholar
  27. Lynch A, Harvey J, Aylott M, Nicholas E, Burman M, Siddiqui A, Walker S, Rees R (2003) Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis 18(4):345–353CrossRefPubMedGoogle Scholar
  28. Mitchell ID, Lambert TR, Burden M, Sunderland J, Porter RL, Carlton JB (1995) Is polyploidy an important genotoxic lesion. Mutagenesis 10(2):79–83CrossRefPubMedGoogle Scholar
  29. Mitelman F, Kolnig A-M, Strömbeck B, Norrby R, Kromann-Andersen B, Sommer P, Wadstein J (1988) No cytogenetic effects of quinolone treatment in humans. Antimicrob Agents Chemother 32:936–937PubMedGoogle Scholar
  30. Morimoto K, Wolff S (1980) Cell cycle kinetics in human lymphocyte cultures. Nature 288:604–606CrossRefPubMedGoogle Scholar
  31. Mukherjee A, Sen S, Agarwal K (1993) Ciprofloxacin: mammalian DNA topoisomerase type II poison in vivo. Mutat Res 301(2):87–92CrossRefPubMedGoogle Scholar
  32. OECD (1997a) OECD guidelines for testing of chemicals, Sect. 4, No. 479. OECD, Organisation for Economic Co-operation and Development, Paris (Adopted 21 July 1997)Google Scholar
  33. OECD (1997b) OECD guidelines for testing of chemicals, Sect. 4, No. 473. OECD, Organisation for Economic Co-operation and Development, Paris (Adopted 21 July 1997)Google Scholar
  34. Pastor N, Cantero G, Campanella C, Cortes F (2005) Endoreduplication induced in cultured Chinese hamster cells by different anti-topoisomerase II chemicals. Evidence for the essential contribution of the enzyme to chromosome segregation. Mutat Res 582:11–19PubMedGoogle Scholar
  35. Perry P, Wolff S (1974) New Giemsa method for the differential staining of sister chromatids. Nature 251:156–158CrossRefPubMedGoogle Scholar
  36. Singh AC, Kumar M, Jha AM (2003) Genotoxicity of lomefloxacin—an antibacterial drug in somatic and germ cells of Swiss albino mice in vivo. Mutat Res 535:35–42PubMedGoogle Scholar
  37. Sumner AT (1998) Induction of diplochromosomes in mammalian cells by inhibitors of topoisomerase II. Chromosoma 107:486–490CrossRefPubMedGoogle Scholar
  38. Takei M, Fukuda H, Kishii R, Hosaka M (2001) Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 45:3544–3547CrossRefPubMedGoogle Scholar
  39. Yague G, Morris JE, Pan X-S, Gould KA, Fisher LM (2002) Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerase mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother 46:413–419CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.International Institute of Biotechnology and ToxicologyKancheepuram DistrictIndia
  2. 2.ToxiConSeilRiedtwilSwitzerland

Personalised recommendations